Novo Nordisk to re-initiate Phase III development of liraglutide for obesity

23 June 2010

Danish insulin giant Novo Nordisk has decided to re-initiate the global Phase III development program of its diabetes drug of liraglutide for the treatment of obesity.

Following the US approval of Victoza (liraglutide) for the treatment of type 2 diabetes earlier this year (The Pharma Letter January 26), Novo Nordisk has been in dialogue with the US Food and Drug Administration regarding the further progression of the development program investigating the potential of the compound within obesity. Based on the feedback from the FDA, Novo Nordisk now plans to re-initiate the global Phase III program in the first half of 2011 in clinical trials comprising approximately 5,000 patients.

The re-initiation of liraglutide obesity trials underlines Novo Nordisk's dedication to the development of the liraglutide portfolio, that is the cardiovascular outcomes trial for Victoza (LEADER), the obesity program, the fixed-ratio combination of insulin degludec and liraglutide, and finally a once-weekly version of liraglutide.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK